Entity Details

Primary name ACY2_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP45381
EntryNameACY2_HUMAN
FullNameAspartoacylase
TaxID9606
Evidenceevidence at protein level
Length313
SequenceStatuscomplete
DateCreated1995-11-01
DateModified2021-06-02

Ontological Relatives

GenesASPA

GO terms

Show/Hide Table
GOName
GO:0004046 aminoacylase activity
GO:0005634 nucleus
GO:0005829 cytosol
GO:0006533 aspartate catabolic process
GO:0009066 aspartate family amino acid metabolic process
GO:0016788 hydrolase activity, acting on ester bonds
GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides
GO:0019807 aspartoacylase activity
GO:0022010 central nervous system myelination
GO:0042802 identical protein binding
GO:0046872 metal ion binding
GO:0048714 positive regulation of oligodendrocyte differentiation

Subcellular Location

Show/Hide Table
Subcellular Location
Cytoplasm
Nucleus

Domains

Show/Hide Table
DomainNameCategoryType
IPR007036 Succinylglutamate desuccinylase/aspartoacylaseFamilyFamily
IPR016708 AspartoacylaseFamilyFamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
271900 OMIMCanavan disease (CAND)A rare neurodegenerative condition of infancy or childhood characterized by white matter vacuolization and demyelination that gives rise to a spongy appearance. The clinical features are onset in early infancy, atonia of neck muscles, hypotonia, hyperextension of legs and flexion of arms, blindness, severe mental defect, megalocephaly, and death by 18 months on the average. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00128 Aspartic acidDrugbanksmall molecule
DB01593 ZincDrugbanksmall molecule
DB14487 Zinc acetateDrugbanksmall molecule
DB14533 Zinc chlorideDrugbanksmall molecule
DB14548 Zinc sulfate, unspecified formDrugbanksmall molecule